ESOPHAGEAL SQUAMOUS CELL CARCINOMA

This study tests new drug combinations, including an antibody-drug conjugate called ifinatamab deruxtecan, with the immunotherapy pembrolizumab (with or without chemotherapy) for people with advanced esophageal cancer that cannot be removed by surgery or has spread. About 298 par…

This study tests a new drug called ALE.P02 in people with advanced or spreading squamous cell cancers of the lung, head and neck, cervix, or esophagus. The drug is designed to find and attack cancer cells that have a specific protein (Claudin-1). The main goals are to check the d…

This early-stage study tests a new drug called IDE034 in about 150 adults with advanced solid tumors (like lung, ovarian, or colon cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink …

This study is for people with advanced esophageal cancer that has gotten worse after standard treatments like chemotherapy and immunotherapy. Researchers are testing new drug combinations, with or without the immunotherapy drug pembrolizumab, to see if they can shrink tumors or s…

This study tests whether adding the drug surufatinib to standard chemotherapy, immunotherapy, and radiation can help people with advanced esophageal cancer that cannot be surgically removed. About 69 adults with this type of cancer will receive the combination treatment. The goal…

This study tests whether giving a combination of envafolimab (an immunotherapy) and two chemotherapy drugs before surgery can help shrink tumors in people with locally advanced esophageal cancer. About 26 adults with operable disease will receive the treatment and then have surge…

This early-stage trial tests a drug called sigvotatug vedotin, alone or with other medicines, in people with advanced solid tumors like lung, head and neck, or breast cancer. The goal is to find a safe dose and check for side effects. About 1,000 participants will join this study…

This study is testing a new drug called ivonescimab (AK112) combined with two chemotherapy drugs (albumin-paclitaxel and cisplatin) given before surgery for people with advanced esophageal cancer that can be removed. The goal is to see if this combination can shrink tumors enough…

This study tests whether intensive nutritional support can improve outcomes for people with locally advanced esophageal cancer that cannot be surgically removed yet. Participants receive standard chemotherapy plus immunotherapy, and are randomly assigned to either intensive nutri…

This study tests whether adding the drug adebrelimab to standard chemotherapy before surgery can help shrink tumors in people with locally advanced esophageal squamous cell carcinoma. About 42 participants will receive the combination treatment. The main goal is to see how many p…

This study tests a treatment strategy that uses a biomarker called CPS to personalize therapy for people with locally advanced esophageal cancer. About 90 participants will receive tailored neoadjuvant (pre-surgery) treatment, then undergo surgery. The main goal is to see how man…

This early-stage trial tests a new drug called EVOLVE104 in 160 people with advanced bladder cancer or several types of squamous cell cancer that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) in people with advanced esophageal cancer that has worsened after standard chemotherapy and immunotherapy. About 510 participants will be randomly assigned to receive either I-DXd or another chemotherapy chosen by t…

This study tests a new drug, vebrekotuzumab, for people with advanced esophageal cancer that stopped responding to initial treatment. The drug is designed to deliver a strong cancer-killing agent directly to tumor cells, potentially slowing or shrinking the cancer. About 104 part…

This study tests a new treatment for people with advanced or recurrent esophageal cancer that cannot be removed by surgery. It combines standard chemoradiotherapy with an immunotherapy drug called adebrelimab. The goal is to see if this combination can shrink tumors and improve s…

This early-phase study tests an experimental drug called PF-08046876 in adults with advanced solid tumors (bladder, lung, head/neck, esophagus, or pancreatic cancer) that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to stick to cancer…

This study tests a new experimental drug called GI-101, given alone or with other cancer drugs (pembrolizumab or lenvatinib), in people with advanced solid tumors that have spread. The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults with canc…

This study tests an experimental oral drug called NEO212 in adults with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it can slow tumor growth. About 134 participants will receive NEO212 a…

This study tests a new drug called ivonescimab combined with a short course of radiation for people with advanced esophageal cancer that has gotten worse after initial treatment. The goal is to see if this combination can slow the cancer's growth and improve survival. The study w…

This study tests whether adding a precise internal radiation treatment (brachytherapy) after standard external radiation, chemotherapy, and the immunotherapy drug nivolumab can help prevent esophageal cancer from returning. About 60 adults with advanced esophageal squamous cell c…

This study is testing a drug called tislelizumab combined with chemotherapy as a first treatment for people with advanced stomach or esophageal cancer that cannot be removed by surgery or has spread. It focuses on racial and ethnic minority groups in the US, including Black, Hisp…

This study tests whether adding itraconazole, a widely used antifungal medication, to standard chemotherapy and radiation can improve outcomes for people with esophageal cancer. About 78 participants with resectable tumors will receive itraconazole before surgery. The goal is to …

This study tests whether adding low-dose or standard radiation to the usual combination of immunotherapy and chemotherapy can better control metastatic esophageal squamous cell carcinoma. About 100 adults with stage IVB cancer who have not had prior treatment will participate. Th…

This study tests a new drug called TER-2013 in people with advanced solid tumors (like breast, endometrial, ovarian, lung, head and neck, esophageal, or cervical cancer) that have specific changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and shrinks tu…

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The drug is given alone or with pembrolizumab to see if it's safe and what side effects occur. About 714 participants with cancers like lung,…

This study tests a new drug called PLX-61639 in adults with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken daily by mouth and aims to shrink or control the cancer. The trial will e…

This study tests whether adding the immunotherapy drug adbelimumab to standard chemotherapy and the targeted drug apatinib can help shrink esophageal cancer before surgery. About 35 adults with resectable stage II–IVA esophageal squamous cell carcinoma will receive this combinati…

This study is a registry that collects information on how patients with advanced esophageal, stomach, or gastroesophageal junction cancer are treated in everyday medical practice in Germany. It will include about 1,900 adults who are starting their first palliative therapy. The g…

This early-phase study is testing a new substance called RAD301 to see how it moves through the body and how much radiation it gives off. It involves 9 people: healthy volunteers and patients with certain cancers like pancreatic, lung, or ovarian cancer. The goal is to measure sa…